Malvern (U.K.) Diabetic Foot Conference on May 14-16, 2014 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases,
WALTHAM, Mass --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media
Record number of SENSUS™ devices sold Launch of second generation SENSUS device Strong growth in domestic DPNCheck ® tests Progress toward DPNCheck launch in Japan WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disturbances, today said it plans
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep
Close collaboration with Omron Healthcare in preparation of the Filing WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC-stat
Discussion of Diagnosis and Treatment of Diabetic Peripheral Neuropathy WALTHAM, Mass. --(BUSINESS WIRE)-- Shai N. Gozani , M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto .
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported